The Globe and Mail reports in its Wednesday, Sept. 23, edition that National Bank of Canada Capital Markets analyst Nathan Po has reaffirmed his "outperform" recommendation for DRI Healthcare Trust. The Globe's Darcy Keith writes in the Eye On Equities column that Mr. Po raised his unit target on DRI Healthcare Trust by $2 to $25.50 after the company announced its deal to acquire royalty rights to Tavapadon, a Parkinson's disease treatment. An FDA approval decision is expected within the next nine days. Upon FDA approval, DRI will pay $316-million in exchange for a mid-single digits to low-double digits tiered royalty on net U.S. sales, four annual payments of $23.4-million each, and two potential sales milestones, all of which are subject to a combined $437.5-million cap on total receipts. Mr. Po says in a note, "While Tavapadon is technically a pre-approval investment, the royalty structure and capped return clearly paint the investment as a shorter-duration, lower-risk asset. ... The existing portfolio alone boasts a mid-teen free cash flow yield, marking a compelling entry point for a company with a credible path to exceed its low-teen EBITDA compounded annual growth rate guidance with new deployments."